share_log

Virpax Pharmaceuticals | CORRESP: CORRESP

Virpax Pharmaceuticals | CORRESP: CORRESP

Virpax制药 | CORRESP:信函
美股SEC公告 ·  05/09 12:35

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company seeks to have the registration become effective on May 13, 2024, at 5:00 p.m. Eastern Time. This request was communicated in a letter addressed to Daniel Crawford at the SEC, with the understanding that the company acknowledges its responsibilities under federal securities laws regarding the issuance of securities covered by the statement. Virpax Pharmaceuticals has authorized Leslie Marlow and Melissa Palat Murawsky of Blank Rome LLP to modify or withdraw the acceleration request if necessary. The SEC has been asked to notify these representatives once the acceleration has been granted.
Virpax Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company seeks to have the registration become effective on May 13, 2024, at 5:00 p.m. Eastern Time. This request was communicated in a letter addressed to Daniel Crawford at the SEC, with the understanding that the company acknowledges its responsibilities under federal securities laws regarding the issuance of securities covered by the statement. Virpax Pharmaceuticals has authorized Leslie Marlow and Melissa Palat Murawsky of Blank Rome LLP to modify or withdraw the acceleration request if necessary. The SEC has been asked to notify these representatives once the acceleration has been granted.
Virpax药品公司已正式向美国证券交易所委员会申请加速其于2024年4月18日初次提交的S-1表格注册声明的生效日期。该公司希望该注册在2024年5月13日美国东部时间下午5点生效。该请求以信函形式向SEC的丹尼尔·克劳福德提交,该公司同意其在联邦证券法规下关于发行该声明涵盖的证券的责任。Virpax药品已授权Blank Rome LLP的Leslie Marlow和Melissa Palat Murawsky修改或撤回加速请求,如果必要的话。已要求SEC在加速获得批准后通知这些代表。
Virpax药品公司已正式向美国证券交易所委员会申请加速其于2024年4月18日初次提交的S-1表格注册声明的生效日期。该公司希望该注册在2024年5月13日美国东部时间下午5点生效。该请求以信函形式向SEC的丹尼尔·克劳福德提交,该公司同意其在联邦证券法规下关于发行该声明涵盖的证券的责任。Virpax药品已授权Blank Rome LLP的Leslie Marlow和Melissa Palat Murawsky修改或撤回加速请求,如果必要的话。已要求SEC在加速获得批准后通知这些代表。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息